Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Curvebeam AI Ltd. ( (AU:CVB) ) is now available.
CurveBeam AI Limited announced its quarterly activity report for Q1 FY26, highlighting a 33.3% increase in purchase orders compared to the previous year, driven by sales of its HiRise™ devices. The company also completed a placement to raise A$6.5 million and entered into a significant agreement with a Chinese distributor for exclusive distribution in several territories, including an upfront investment and potential future investments. Additionally, CurveBeam AI is advancing its vendor financing facility and targeting mid-CY26 for FDA clearance of its bone mineral density software module, which could enhance its market positioning.
The most recent analyst rating on (AU:CVB) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a developer of point-of-care specialized medical imaging equipment and AI-enabled SaaS-based clinical assessment solutions. The company focuses on providing advanced medical imaging technologies, particularly CT equipment, to enhance clinical assessments.
Average Trading Volume: 464,747
Technical Sentiment Signal: Sell
Current Market Cap: A$38.36M
For an in-depth examination of CVB stock, go to TipRanks’ Overview page.